Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-03-31 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事关于续聘中审众环会计师事务所（特殊普通合伙）为公司2016年度审计机构的独立意见
Audit Report / Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the reappointment of an audit firm for the 2016 fiscal year. It references the audit firm and the audit engagement but does not contain actual financial statements or detailed audit results. The document is short (493 characters) and serves as an opinion or statement about the audit appointment, not the audit report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. FY 2016
2016-03-31 Chinese
2016年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2016 年度内部控制评价报告' which translates to '2016 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2015, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, which is typically part of audit-related disclosures. It does not present full financial statements or comprehensive annual financial performance, so it is not an Annual Report (10-K). It is not a short announcement or certification but a substantive report on internal control evaluation. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. The document length is under 5,000 characters but contains detailed substantive content, not just an announcement. Therefore, the best classification is AR with high confidence. FY 2015
2016-03-31 Chinese
东海证券股份有限公司关于股份有限公司2015年度之持续督导报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导报告书" (Continuous Supervision Report) issued by Donghai Securities Co., Ltd. regarding Kunming Pharmaceutical Group Co., Ltd. It details the continuous supervision work performed by the sponsor institution following a non-public stock issuance in 2015. The report includes detailed supervisory activities, compliance checks, information disclosure reviews, and confirms no violations or issues during the supervision period. It is a regulatory compliance and supervision report related to the sponsor's ongoing monitoring duties rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on regulatory oversight and compliance. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2016-03-31 Chinese
东海证券股份有限公司关于股份有限公司2015年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from Donghai Securities regarding the continuous supervision and on-site inspection of Kunming Pharmaceutical Group Co., Ltd. for the year 2015. It includes comprehensive checks on corporate governance, internal controls, information disclosure, use of raised funds, related party transactions, external guarantees, major investments, and the company's operating status. The report references regulatory approvals, audit reports, and compliance with stock exchange rules. The content is focused on the results of an audit-like inspection rather than a full annual report or financial statement. It is a standalone audit-related report issued by the sponsor institution after a regulatory approval and inspection process. The document length is 3560 characters, which is substantial but not a full annual report. It is not an announcement or a brief notice but a detailed inspection report. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2015
2016-03-31 Chinese
关于为控股公司提供担保的公告
Board/Management Information Classification · 100% confidence The document is a company announcement from Kunming Pharmaceutical Group Co., Ltd. It announces the appointment of Mr. Dai Xiaochang as the company's legal representative and president, including his detailed biography and career history. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses on management changes, specifically the appointment of a senior executive. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2016-03-30 Chinese
2015年度审计与风险控制委员会履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2015年度审计与风险控制委员会履职报告" which translates to the "2015 Annual Audit and Risk Control Committee Performance Report". It details the activities and oversight performed by the Audit and Risk Control Committee during 2015, including meetings held, review of internal controls, audit plans, and communication with external auditors. The document focuses on the committee's role in supervising the audit process and internal controls rather than presenting the full audited financial statements or the full annual report. It is a standalone report about audit committee activities and audit oversight, not the full Annual Report (10-K) or the Audit Report (AR) itself. Given the nature of the content, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related audit committee reports. The document length is under 5,000 characters, but it is a substantive report, not merely an announcement or certification, so it is not RPA or RNS. Therefore, the classification is AR with high confidence. FY 2015
2016-03-30 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.